Loading interface...

Eurelix 0.25 mg Injection

Manufactured bySamarth Life Sciences Pvt. Ltd.
ContainsCetrorelix
Description
Eurelix 0.25 mg Injection is used along with other hormonal medicines such as human chorionic gonadotropin (hCG) in women who are under fertility treatment (controlled ovarian stimulation) for preventing the release of a premature egg from the ovary. Use of this medicine in pregnant women is not recommended.

Side effects

Major & minor side effects for Eurelix 0.25 mg Injection

  • Hypersensitivity
  • Ovarian hyperstimulation syndrome (OHSS)
  • Nausea
  • Headache
  • Swelling of ankles or feet
  • Decreased urine output
  • Shortness of breath
  • Rapid weight gain

Uses of Eurelix 0.25 mg Injection

What is it prescribed for?

  • Prevention of premature ovulation in women undergoing controlled ovarian stimulation
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The effect of this medicine can be observed within 1 hour of administration of the 3 mg dose and within 2 hours of administration of the 0.25 mg dose.
  • How long do the effects of this medicine last?
    Eurelix 0.25 mg Injection remains active in the body for 24 hours after a 0.25 mg dose and for 4 days after a 3 mg dose.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit forming tendencies were reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women.

Allergy

This medicine is not recommended for use in patients with a known allergy to cetrorelix or any other components present along with it.

Pregnancy

This medicine is not recommended for use in pregnant women.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women.

Breast-feeding

This medicine is not recommended for use in breastfeeding women.
General warnings

Use in pediatrics

This medicine is not recommended for use in children and adolescents.

Elevated liver enzymes

This medicine may cause elevation of liver enzymes up to 3 times of the upper limit of normal. Close monitoring of liver enzymes is recommended during treatment with this medicine.

Geriatric use

Eurelix 0.25 mg Injection is not recommended for use in patients above 65 years of age.

Missed Dose

If you miss an appointment for a dose of Eurelix 0.25 mg Injection injection, contact your doctor immediately and schedule the dose as soon as possible.

Overdose

Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine
Disease interactions

Disease

Information not available.
Food interactions
Information not available.
Lab interactions
Information not available.
Eurelix 0.25 mg Injection injection is usually administered by a qualified healthcare professional. Follow all the instructions given by your doctor. Consult the doctor if you experience any undesirable effects. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

Does not cause sleepiness

How it works
Eurelix 0.25 mg Injection acts by blocking the action of certain natural hormones responsible for the release of an egg from the ovary. This helps in preventing the premature release of the egg.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Gonadotropin releasing hormone (GnRH) antagonist

Schedule

N/A

CETROTIDE - cetrorelix acetate [Internet]. Dailymed.nlm.nih.gov. 2017 [cited 21 August 2017]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&audience=consumer

[Internet]. 2017 [cited 21 August 2017]. Available from:

https://www.medicines.org.uk/emc/medicine/8744

Cetrorelix - DrugBank [Internet]. Drugbank.ca. 2017 [cited 21 August 2017]. Available from:

https://www.drugbank.ca/drugs/DB00050

Cetrorelix (substance) [Internet]. Snomedbrowser.com. 2017 [cited 21 August 2017]. Available from:

http://www.snomedbrowser.com/Codes/Details/395906005

[Internet] Genome.jp. 2017 [cited 21 August 2017]. Available from:

http://www.genome.jp/dbget-bin/www_bfind_sub?mode=bfind&max_hit=1000&dbkey=all&keywords=cetrorelix
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 29 Aug 2017

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.